Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Etudes cliniques et résultats Sanofi pharma, incluant Sanofi Genzyme – Lettre F

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

FATTY ACID AMIDE HYDROLASE INHIBITOR

Not marketed

Cancer pain

ACT11705

NA

EudraCT: 2011-002557-56

FATTY ACID AMIDE HYDROLASE INHIBITOR

Not marketed

Major Depressive Disorder

DFI10560

FIDELIO

EudraCT: 2008-001718-26

FEDRATINIB

Not marketed

Myelofibrosis

ARD12888

NA

NCT01692366

FEDRATINIB

Not marketed

Myelofibrosis

ARD12888

NA

NCT01692366

FEDRATINIB

Not marketed

Hematopoietic Neoplasm

ARD12042

NA

NCT01420783

FEDRATINIB

Not marketed

Hematopoietic Neoplasm

ARD11936

NA

NCT01420770

FEDRATINIB

Not marketed

Neoplasm malignant

TES13519

NA

NCT01836705

FEDRATINIB

Not marketed

Hematopoietic Neoplasm

ARD12181

JAKARTA2

NCT01523171

FEDRATINIB

Not marketed

Myelofibrosis

EFC12153

JAKARTA

EudraCT: 2011-001897-25

FEDRATINIB

Not marketed

Solid Tumor

INT12497

NA

NCT01585623

FEDRATINIB

Not marketed

Renal Impairment

POP13449

NA

NCT01763190

FEDRATINIB

Not marketed

Hepatic Impairment

POP13450

NA

NCT01762462

FERROQUINE

Not marketed

Malaria

ACT10420

NA

NCT00563914

FERROQUINE

Not marketed

Malaria

ACT14655

NA

NCT03660839

FERROQUINE

Not marketed

Malaria

DRI10382

FARM

NCT00988507

FERROQUINE

Not marketed

Malaria

DRI12805

FALCI

NCT02497612

FEXOFENADINE HYDROCHLORIDE

Allegra

Urticaria

M016455_4001

NA

NA

FEXOFENADINE HYDROCHLORIDE

Allegra

Urticaria

M016455A_4121

NA

NA

FEXOFENADINE HYDROCHLORIDE

Allegra

Rhinitis, Seasonal

M016455_4124

NA

NCT00636870

FEXOFENADINE HYDROCHLORIDE

Allegra

Cognition

M016455A_4139

NA

NCT00637455

FEXOFENADINE HYDROCHLORIDE

Allegra

Urticaria

M016455A_4143

NA

NA

FEXOFENADINE HYDROCHLORIDE

Allegra

Urticaria

M016455A_4144

NA

NCT00547768

FEXOFENADINE HYDROCHLORIDE

Allegra

Seasonal allergy

M016455A_4145

NA

NCT00637585

FEXOFENADINE HYDROCHLORIDE

Allegra

Seasonal allergy

M016455A_4146

NA

NCT00638118

FEXOFENADINE HYDROCHLORIDE

Allegra

Cat allergy symptoms

M016455A_4148

NA

NCT00637884

FEXOFENADINE HYDROCHLORIDE

Allegra

Seasonal Allergic Rhinitis

LPS15332

FEXPOLSAR

NCT03664882

FEXOFENADINE HYDROCHLORIDE

Allegra

Seasonal Allergic Rhinitis

M016455A_4149

NA

NCT00637611

FEXOFENADINE HYDROCHLORIDE

Allegra

Seasonal Allergic Rhinitis

M016455C_4001

NA

NCT00741897

FEXOFENADINE HYDROCHLORIDE

Allegra

Rhinitis Perennial

SFY10717

NA

NCT01244217

FEXOFENADINE HYDROCHLORIDE

Allegra

Atopic Dermatitis

SFY10718

NA

NCT01244230

FEXOFENADINE HCL - PSEUDOEPHEDRINE HCL COMBINATION

Allegra-D

Rhinitis Perennial

EFC11243

NA

NCT01306721

FEXOFENADINE HCL - PSEUDOEPHEDRINE HCL COMBINATION

Allegra-D

Allergic Rhinitis

FEXHYL06934

NA

NCT02175485

FGFR NHIBITOR

Not marketed

Solid Tumors

PRN1371-001

NA

NCT02608125

FLUOROURACIL

Carac

Keratosis

DL6025-0201

NA

NCT00377273

FRESOLIMUMAB

Not Marketed

Glomerulosclerosis

GC1008FSGS03110

NA

EudraCT: 2012-002365-35

FUROSEMIDE

Lasix, Eutensin, Lasilix

Chronic Renal Failure

FUROSL06121

NA

NCT01724788

FEXOFENADINE - PHENYLEPHRINE

Not Marketed

Allergic Rhinitis

FEXHYL07477

NA

NCT02401191

FRESOLIMUMAB

Not Marketed

Glomerulosclerosis

DRI12792

NA

EudraCT: 2012-002365-35

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted